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Background: With the irrational and massive use of
Antibiotics in underdeveloped and developing countries,
resultantly there was increased Resistance to Antibiotics
and with the increased interest in herbal medicine and use
of honey for various therapeutic purposes has led to the
search for new antibacterial honeys. Hence a study was con-
ducted to assess the antibacterial and fungicidal activity of
six honeys locally produced under natural and farm environ-
ment and their comparison with the commercially available
therapeutic honeys (including Medihoney® and rewa rewa
honey).
Methods: An agar dilution method was used to assess the
activity of honeys against 15 bacteria and one yeast. The
honeys were tested at eight concentrations ranging from 1%
to 50%.
Results: All 15 bacteria were inhibited by all honeys used
in this study with only the yeast Candida albicans not inhib-
ited by the honeys at 20%. Little antibacterial activity was
seen at honey concentrations <5%, with minimal inhibition
at 5%. No honey was able to produce complete inhibition
of bacterial growth at concentration up to 20% but with the
increase in concentration 40% honey obtained from wild bee
produces remarkable inhibition. Although Medihoney® and
rewa rewa had the overall good activity but the activity of
naturally produced (by wild bee) local honey was even better
than those. But the locally produced honeys by commercial
beekeepers had poor inhibitory activity for some, but not
for all bacteria.
Conclusions: Honeys other than those commercially
available as antibacterial honeys can have equivalent
antibacterial activity if they produced through hygienic
methods. The newly identiﬁed antibacterial honeys may
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Background: Tigecycline, a novel glycylcycline class
agent (ﬁrst in class), has been utilized for serious multidrug-
resistant (MDR) pathogen infections in several global
locations for 1—3 years. This prospective in vitro multi-
center trial evaluates nearly 4,000 pathogens from Japan
(2006—2007).
Methods: A total of 3,902 isolates (19 medical centers)
were processed by reference broth microdilution methods
in a single central laboratory. CLSI methods were applied
and breakpoints found in CLSI M100-S18 (2008) or USA-
FDA Tygacil® package insert were used. The most prevalent
organisms were: S. aureus (SA; 1,198), S. pneumoniae (SPN;
459), E. coli and Klebsiella (199 each), CoNS (198), Enter-
obacters (197), enterococci (195) and Acinetobacters (193).
All concurrent QC was acceptable.
Results: Against Gram-positive cocci, tigecycline MIC50/90
values were: SA (0.12/0.5mg/L), enterococci and CoNS
(0.12/0.25), SPN (≤0.03/0.06), and -haemolytic (BHS) or
viridans group streptococci (≤0.03/0.06); all susceptible
except 3 MRSA (MIC at 1mg/L). Among Enterobacteri-
aceae, tigecycline inhibited 100.0, 99.0 and 100.0% of
E. coli, Klebsiella and Enterobacters at ≤2mg/L, respec-
tively. P. mirabilis and S. marcescens were less susceptible
to tigecycline (MIC90 range, 1 to 4mg/L). Acinetobac-
ters (193) had MIC values ranging to 4mg/L; 99.0% at
≤2mg/L and 1.6% carbapenem-resistant. P. aeruginosa were
generally tigecycline-resistant (MIC90, >4mg/L). 14.5% of
group B were levoﬂoxacin-resistant (clonal with multi-
ple QRDR mutations in 7 sites). ESBL rates were only
2.0—6.5% in E. coli and Klebsiella, and ﬂuoroquinolones
and trimethoprim/sulfamethoxazole resistances were high-
est (20.1—21.1%) in E. coli.
Conclusions: Tigecycline was observed to be active
against nearly all tested species from Japanese medical
centers for year 2003—2004 strains, and in this prospective
sample report remains similarly active (2006—2007 isolates).
Resistant subsets (MRSA, ESBL enteric bacilli, MDR Acine-
tobacters) were generally inhibited at USA-FDA-susceptible
breakpoints for tigecycline. Possible use of tigecycline
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Background: Development of antibiotic resistance is one
of the most common problems in medicine. Thus, discover-
ing of new antibacterial compounds is interesting. Marine
algae are rich sources of bioactive metabolites that could
be effective as antimicrobial agents. The aim of this in-vitro
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study, was to test for antibacterial activity of a green alga,
Caulerpa sertularioides from the Persian Gulf.
Methods: The extract from C. sertularioides was pre-
pared by 20minutes boiling of alga in 20% glycerine solution
and it was then sterilized using the ﬁlteration. A bacterial
concentration of 500000 colony forming units (CFU)/ml of
Staphylococcus epidermidis (ATCC 14990) as a gram posi-
tive or Escherichia coli (ATCC 25922) as a gram negative
bacterium were tested with different concentrations of the
extract in Mueller-Hinton broth for evaluation of antibacte-
rial effect. Controls without the extract were treated by the
same way. Results. The extract showed antibacterial activ-
ity against S. epidermidis and E. coli in the concentrations
of 34mg/ml and 27.2mg/ml, respectively.
Conclusion: C. sertularioides could be a suitable source
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Background: Beta-lactam antibiotics efﬁcacy depends on
the duration of time in which serum concentration exceeds
MIC. The aim of open prospective randomized study was to
compare clinical and microbiolgical efﬁcacy of continuous
infusion versus intermittent administration of meropenem
in critically ill patients.
Methods: Patients admitted to interdisciplinary ICU
suffering from severe infection indicated to meropenem
administration were randomized to receive either a 2 g
iv loading dose of meropenem followed by a daily 4 g
continuous infusion (CONTINUOUS group) or intermittent
administration of 2 g of meropenem iv in every 8 h
(INTERMITTENT group). Antibiotic therapy was stopped at
improvement of clinical state and signs of subsidence of
infection (body temperature below 38,3 ◦C, white blood
count <10000/mm3 or decrease below 25% of maximal value,
C-reactive protein - CRP ≤100mg/l). Microbiological efﬁ-
cacy was evaluated as success (eradication or presumed
eradication) or failure (persistence or rezistence devel-
opment). The age, gender, APACHE II score, SOFA score,
length of ICU stay, length of mechanical ventilation, type
of infection were assessed. Success, failure and length of
meropenem therapy and total dose of meropenem were
evaluated. Mann-Whitney, unpaired t-test and Chi-squared
test were used accordingly; p < 0,05 was considered statis-
tically signiﬁcant.
Results: A total of 84 patients (55 men and 29 women)
were enrolled and randomized in CONTINUOUS (n = 42)
and INTERMITTENT (n = 44) group. No signiﬁcant differ-
ences between CONTINUOUS and INTERMITTENT group in
assessed parameters were found except for total dose of
meropenem.
Conclusion: Continuous infusion and intermittent admin-
istration of meropenem in critically ill patients provided
equivalent clinical and microbiological outcome. Compared
with intermittent application, continuous infusion signif-
icantly decreased the total dose of meropenem. Grant
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Background: In 2005, tigecycline (TIG) a novel glycylcy-
cline was approved in the US for treatment of complicated
skin and skin structure infections (cSSSI) and complicated
intra-abdominal infections (cIAI). As such, it is important to
continue to monitor TIG activity against target pathogens for
these indications. This study reports the in vitro activity of
TIG against Enterobacteriaceae (EN) and Acinetobacter spp.
(AC) as observed during development (‘01—‘04), and during
the years following its approval for use (‘05, ‘06 and ‘07).
The results were further stratiﬁed to determine whether any
potential variability in TIG activity against EN and AC exists
according to patient location (PL) and specimen source (SS).
Methods: EN and AC isolates were collected from mul-
tiple locations across all nine US Bureau of Census regions
during the following years (Y): ‘01—‘04 (EN: 1330, AC: 224),
‘05 (EN: 1151, AC: 77), ‘06 (EN: 958, AC: 255), and ‘07 (EN:
599, AC: 114). Isolates were centrally tested using broth
microdilution according to current CLSI standards. TIG activ-
ity was analyzed by patient location (PL; outpatient [OP],
intensive-care unit [ICU], and inpatient non-ICU [IP]) and by
specimen source (SS; blood [BL], respiratory [RP], urine [UR:
EN only], and skin and skin structure [SST]). EN FDA break-
points (BPs) were used to interpret all TIG MIC results (as
BPs for TIG against AC do not currently exist).
Results: Against EN overall, TIG had an MIC90 of 1mg/L
in each study period (‘01—‘04, ‘05, ‘06, and ‘07), and EN
isolates were ≥99% susceptible (S) to TIG throughout. The
activity of TIG for each study period was consistent by MIC90,
regardless of PL (MIC90 = 1mg/L against OP, ICU, and IP) or
SS (MIC90 = 1mg/L against BL, RP, and SST, 0.5—1mg/L for
UR isolates). In the most recent period evaluated (‘07), EN
isolates were ≥99% S to TIG for all PL and SS evaluated.
Against AC overall, TIG had an MIC90 of 2mg/L in ‘01—‘04
and ‘07 and 1mg/L in ‘05 and ‘06. The % S of AC went from
97% in ‘01—‘04 to ≥99.5% in ‘05, ‘06 and ‘07. For each study
period, little variation in TIG MIC90 was observed either by
PL or SS (1—2mg/L). In ‘07, 100% of tested acinetobacter
were susceptible to TIG (EN BPs were utilized for AC).
Conclusion: Little to no alteration in the in vitro activ-
ity of TIG against EN and AC was apparent by MIC90 over the
